Want to see SE:MAGLE full AI Analyst Report?
MAGLE Stock Chart & Stats
kr17.20
-kr1.20(-3.66%)
At close: 4:00 PM EST
kr17.20
-kr1.20(-3.66%)
Day’s Range― - ―
52-Week Rangekr0.39 - kr23.60
Previous CloseN/A
Volume1.20K
Average Volume (3M)1.06K
Market Cap
kr12.11M
Enterprise Valuekr363.38
Total Cash (Recent Filing)kr2.08M
Total Debt (Recent Filing)kr343.99M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.23
Shares Outstanding30,263,191
10 Day Avg. Volume1,291
30 Day Avg. Volume1,058
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.92
Price to Sales (P/S)1.28
P/FCF Ratio-8.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.4
Revenue Forecast (FY)kr285.10M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthPositive TTM revenue growth indicates continued demand for the company’s pharmaceutical development, manufacturing, and related services. Sustained top-line expansion can improve operating leverage if growth continues and the current cost base is better controlled.
Gross MarginA gross margin of about 54% shows that the underlying products and services retain meaningful value after direct costs. This provides a foundation for eventual earnings recovery, although management must reduce operating costs to convert gross profit into sustainable net income.
Integrated Business ModelOperating across drug development, manufacturing, and related services gives Magle multiple ways to participate in pharmaceutical value creation. This breadth may support customer relationships and revenue diversification across internal products and external projects over time.
Bears Say
Severe Profitability DeclineThe sharp shift from prior profitable years to a deeply negative net margin indicates that the current cost structure is overwhelming gross profit. Persistent losses could restrict reinvestment, weaken equity, and make the revenue growth trend less valuable to shareholders.
Sustained Cash BurnNegative operating and free cash flow show that reported business activity is not currently funding operations. If cash generation does not recover, the company may need additional financing, asset actions, or spending reductions, limiting strategic flexibility over the next several months.
Higher LeverageDebt exceeding equity and a reduced equity cushion increase balance-sheet vulnerability while losses continue. Higher leverage can raise funding dependence and constrain investment in pharmaceutical development, manufacturing capacity, and customer programs if performance remains weak.
Magle Chemoswed Holding AB News
MAGLE FAQ
What was Magle Chemoswed Holding AB’s price range in the past 12 months?
Magle Chemoswed Holding AB lowest stock price was kr0.39 and its highest was kr23.60 in the past 12 months.
What is Magle Chemoswed Holding AB’s market cap?
Magle Chemoswed Holding AB’s market cap is kr12.11M.
When is Magle Chemoswed Holding AB’s upcoming earnings report date?
Magle Chemoswed Holding AB’s upcoming earnings report date is Nov 02, 2026 which is in 67 days.
How were Magle Chemoswed Holding AB’s earnings last quarter?
Magle Chemoswed Holding AB released its earnings results on Aug 12, 2026. The company reported -kr0.821 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Magle Chemoswed Holding AB overvalued?
According to Wall Street analysts Magle Chemoswed Holding AB’s price is currently Overvalued.
Does Magle Chemoswed Holding AB pay dividends?
Magle Chemoswed Holding AB pays a Notavailable dividend of kr0.35 which represents an annual dividend yield of N/A. See more information on Magle Chemoswed Holding AB dividends here
What is Magle Chemoswed Holding AB’s EPS estimate?
Magle Chemoswed Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Magle Chemoswed Holding AB have?
Magle Chemoswed Holding AB has 30,263,191 shares outstanding.
What happened to Magle Chemoswed Holding AB’s price movement after its last earnings report?
Magle Chemoswed Holding AB reported an EPS of -kr0.821 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Magle Chemoswed Holding AB?
Currently, no hedge funds are holding shares in SE:MAGLE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Magle Chemoswed Holding AB
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process development and production of Active Pharmaceutical Ingredients (APIs), as well as the innovation and manufacturing of advanced wound care and diagnostic products, primarily leveraging its proprietary degradable starch microsphere technology. Its API portfolio features Warfarin sodium, used as an anticoagulant; Melperone hydrochloride, an antipsychotic agent; Isradipine, a calcium channel blocker for hypertension; Amantadine sulfate, for central nervous system disorders; and Benserazide hydrochloride, utilized with L-Dopa in Parkinson's disease treatment. Furthermore, Magle Chemoswed offers a range of medical devices for advanced wound care, surgical diagnostics, and drug delivery. These include EmboCept S, a microsphere-based device for vascular occlusion in liver and lung tumors; SmartGel, an innovative non-allergenic hydrogel derived from their microsphere platform; SmartPAN, a diagnostic tool for detecting pancreatic fluid leakage during surgical procedures; and EmboCept M, designed for managing benign prostatic hyperplasia. The company provides contract services to the pharmaceutical and medical device industries. Founded in 1944, Magle Chemoswed Holding AB (publ) operates as a subsidiary of Magle AB.
Technical Analysis
BioInvent International AB
―
Scandinavian ChemoTech AB Class B
―
Elicera Therapeutics AB
―
Spago Nanomedical AB
―
Cantargia AB
―